News

Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Ozempic maker Novo Nordisk on track for its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo's new CEO faces sceptical investors with Wegovy US sales in focus
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
Trending tickers: Novo Nordisk, Starbucks, SoFi Technologies, BAE Systems and Taylor Wimpey
In a release on Tuesday, Novo Nordisk cut its expected full-year sales growth to 8%-14%, down from the 13%-21% it had ...
Novo Nordisk Shares Plummet as Competition Weighs on Sales
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Obesity Drugmaker Novo Nordisk Plunges as It Cuts Forecasts Again
Novo now expects 2025 sales growth of 8%-14% in local currencies, down from its previous 13-21% range. It also lowered its ...
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition
Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...
Stock Movers: Novo Nordisk, Palo Alto, Union Pacific
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...